Data lock point for this RMP	06.10.2020	RMP Version number	2.1
Date of final sign off	06.10.2020		

Summary of the risk management plan for Kaliumklorid Orifarm

This is a summary of the risk management plan (RMP) for Kaliumklorid Orifarm. The RMP details no important risks of Kaliumklorid Orifarm and no missing information.

Kaliumklorid Orifarm´s summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Kaliumklorid Orifarm should be used.

I. The medicine and what it is used for

Kaliumklorid Orifarm is authorised for treatment of low potassium levels in the bloodstream (Hypokalaemia) and prophylactic treatment during treatment with diuretics.

It contains potassium chloride as the active substances and it is given orally as hard capsules.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Kaliumklorid Orifarm together with measures to minimise such risks and the proposed studies for learning more about Kaliumklorid Orifarm's risks, are outlined below.

- Product information including warnings, precautions, and advice on correct use. Package leaflet is enclosed in the package and the Summary of Product Characteristics (and Package Leaflet) are published on the webpage of the Medicines Agencies.

Together, these measures constitute *routine risk minimisation* measures.

If important information that may affect the safe use of Kaliumklorid Orifarm is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Kaliumklorid Orifarm are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Kaliumklorid Orifarm. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

Summary of safety concerns	
Important identified risks	• None

Data lock point for this RMP	06.10.2020	RMP Version number	2.1
Date of final sign off	06.10.2020		

Summary of safety concerns	
Important potential risks	• None
Missing information	• None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Kaliumklorid Orifarm.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Kaliumklorid Orifarm.